FIT Biotech Oy: Resolutions of the Annual General
Post# of 301275
FIT BIOTECH OY
Company announcement April 7, 2017 at 13.30 EET
Resolutions of the Annual General Meeting and the Board of FIT Biotech Oy on April 7, 2017
1. Annual Accounts, Board of Directors and Auditors
The Annual General Meeting approved the annual accounts of the company and discharged the members and the vice members of the Board of Directors and the CEO from liability for the financial period of 2016.
The Annual General Meeting confirmed, according to the proposal of the Board of Directors, the number of the members of the Board of Directors as five (5) and that Chitra Bharucha, Erkki Pekkarinen, Eero Rautalahti and Rabbe Slätis be re-elected to the Board and that Anne-Maria Salonius be elected as new members for the term expiring at the end of the next Annual General Meeting following the election.
The Annual General Meeting resolved that the members of the Board be paid the following remuneration for the term ending at the end of the 2018 Annual General Meeting:
Chairperson of the Board EUR 3,000 per month.
Other members of the Board (including deputy chairperson) will be paid a meeting compensation of EUR 800 for each physical meeting in which the Board member is personally in attendance throughout the duration of the Board meeting.
The members of the Board who reside abroad will be paid a meeting compensation of EUR 500 also for meetings which they attend by telephone, provided that the member is in attendance via telephone throughout the duration of the Board meeting and that the Board meeting would otherwise be considered a physical meeting.
In addition, the chairperson of the Board and other Board members will be paid for their reasonable travelling expenses to Board meetings.
The Annual General Meeting resolved that audit firm PricewaterhouseCoopers Oy be re-elected as the auditor, Janne Rajalahti, APA as the responsible auditor, for the term ending at the end of the next Annual General Meeting. The auditors shall be reimbursed in accordance with the auditors' reasonable invoice approved by the company.
2. Use of the profit shown on the balance sheet
The Annual General Meeting resolved that no dividends be distributed for the 2016 financial period and that the financial result of EUR -3,651,186.26 for the financial period be transferred to the profit/loss account.
3. Board's assembly meeting
In its assembly meeting right after the Annual General Meeting, the Board of Directors elected Rabbe Slätis as the Chairperson.
The minutes of the Annual General Meeting will be available for viewing at the company's head office and the website on April 21, 2017 at the latest.
FIT BIOTECH OY
Board of Directors
Further information:
Rabbe Slätis
FIT Biotech Oy
Tel: +358 40 8406749
E-mail: rabbe.slatis@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
(0)
(0)